JP2019508433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508433A5 JP2019508433A5 JP2018546036A JP2018546036A JP2019508433A5 JP 2019508433 A5 JP2019508433 A5 JP 2019508433A5 JP 2018546036 A JP2018546036 A JP 2018546036A JP 2018546036 A JP2018546036 A JP 2018546036A JP 2019508433 A5 JP2019508433 A5 JP 2019508433A5
- Authority
- JP
- Japan
- Prior art keywords
- liv
- adc
- subject
- pharmaceutical composition
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022006944A JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308639P | 2016-03-15 | 2016-03-15 | |
| US62/308,639 | 2016-03-15 | ||
| US201662317792P | 2016-04-04 | 2016-04-04 | |
| US62/317,792 | 2016-04-04 | ||
| US201662367510P | 2016-07-27 | 2016-07-27 | |
| US62/367,510 | 2016-07-27 | ||
| PCT/US2017/022541 WO2017161007A1 (en) | 2016-03-15 | 2017-03-15 | Combination therapy using a liv1-adc and a chemotherapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006944A Division JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508433A JP2019508433A (ja) | 2019-03-28 |
| JP2019508433A5 true JP2019508433A5 (https=) | 2020-04-23 |
Family
ID=59852409
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546036A Pending JP2019508433A (ja) | 2016-03-15 | 2017-03-15 | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2022006944A Pending JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A Pending JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006944A Pending JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A Pending JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11325980B2 (https=) |
| EP (1) | EP3429626A4 (https=) |
| JP (3) | JP2019508433A (https=) |
| KR (3) | KR20180121571A (https=) |
| CN (1) | CN108697801A (https=) |
| AU (2) | AU2017235545A1 (https=) |
| BR (1) | BR112018068129A2 (https=) |
| CA (1) | CA3016485A1 (https=) |
| EA (1) | EA201891968A1 (https=) |
| IL (1) | IL261505A (https=) |
| MA (1) | MA45324A (https=) |
| MX (2) | MX2018010847A (https=) |
| SG (2) | SG10201912908QA (https=) |
| WO (1) | WO2017161007A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6105481B2 (ja) | 2010-12-06 | 2017-03-29 | シアトル ジェネティクス，インコーポレーテッド | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| MA50943A (fr) * | 2017-12-01 | 2020-10-07 | Seattle Genetics Inc | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein |
| CN113015750A (zh) | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| BR112022011268A2 (pt) * | 2019-12-09 | 2022-09-06 | Seagen Inc | Terapia de combinação com antagonista de liv1-adc e pd1 |
| MX2023003404A (es) * | 2020-09-28 | 2023-03-31 | Seagen Inc | Anticuerpos anti-l1vi humanizados para el tratamiento del cancer. |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| JP2026509871A (ja) * | 2023-03-15 | 2026-03-25 | 浙江博鋭生物製薬有限公司 | 抗ｌｉｖ－１抗体及び抗ｌｉｖ－１抗体薬物複合体並びにその薬物的使用 |
| WO2025162207A1 (zh) * | 2024-01-31 | 2025-08-07 | 上海复宏汉霖生物技术股份有限公司 | 抗liv1抗体及使用方法 |
| WO2026057076A1 (zh) * | 2024-09-14 | 2026-03-19 | 杭州博之锐生物制药有限公司 | 基于抗liv-1抗体-药物偶联物的耐药癌症的治疗 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69228300T2 (de) | 1991-08-22 | 1999-09-23 | Becton Dickinson And Co., Franklin Lakes | Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| DE69737788T2 (de) | 1996-10-31 | 2008-03-13 | Abbott Laboratories, Abbott Park | Reagenzien und methoden zum nachweis von erkrankungen der brust |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
| WO1999023230A1 (en) | 1997-10-31 | 1999-05-14 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| EP1032706A1 (en) | 1997-11-18 | 2000-09-06 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| CA2316397A1 (en) | 1997-12-24 | 1999-07-08 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| WO2000008210A1 (en) | 1998-08-04 | 2000-02-17 | Diadexus Llc | A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| JP2002527066A (ja) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | 転移性乳癌および結腸癌調節遺伝子 |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| IL150592A0 (en) | 2000-01-25 | 2003-02-12 | Genentech Inc | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| AU2001264099A1 (en) | 2000-06-13 | 2001-12-24 | University College Cardiff Consultants Ltd. | Zinc transporters |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030068636A1 (en) | 2001-06-21 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| WO2003004989A2 (en) | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR101104655B1 (ko) | 2002-03-08 | 2012-01-13 | 애보트 바이오테라퓨틱스 코포레이션 | 암 항원 ｔｍｅｆｆ２ 에 대한 항체 및 이의 용도 |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| JP2006520194A (ja) | 2003-01-27 | 2006-09-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｉｇｓｆ９およびｌｉｖ−１を使用して癌を処置するための組成物および方法 |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| CN101309933A (zh) * | 2005-09-07 | 2008-11-19 | 米迪缪尼有限公司 | 毒素偶联的Eph受体抗体 |
| US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
| CN101622273A (zh) | 2006-04-13 | 2010-01-06 | 诺瓦提斯疫苗和诊断公司 | 治疗、诊断或检测与liv-1过量表达相关的癌症的方法 |
| WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| BRPI0810561A2 (pt) | 2007-04-23 | 2019-09-24 | Wyeth Corp | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. |
| AU2008328726B2 (en) | 2007-11-30 | 2014-06-12 | Glaxo Group Limited | Antigen-binding constructs |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| WO2010045234A1 (en) | 2008-10-14 | 2010-04-22 | University Of Louisville Research Foundation, Inc. | Methods of optimizing treatment of estrogen-receptor positive breast cancers |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| US8728730B2 (en) | 2009-09-03 | 2014-05-20 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| JP6105481B2 (ja) | 2010-12-06 | 2017-03-29 | シアトル ジェネティクス，インコーポレーテッド | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| WO2013055874A2 (en) * | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| CA2873111A1 (en) * | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
| DE202012006349U1 (de) | 2012-07-03 | 2013-07-05 | Schuster Engineering Gmbh | Schiffsladeanordnung |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| JP6406647B2 (ja) * | 2013-07-02 | 2018-10-17 | 公益財団法人がん研究会 | 細胞性免疫誘導ワクチン |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| MA50943A (fr) | 2017-12-01 | 2020-10-07 | Seattle Genetics Inc | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein |
| CN113015750A (zh) | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| BR112022011268A2 (pt) | 2019-12-09 | 2022-09-06 | Seagen Inc | Terapia de combinação com antagonista de liv1-adc e pd1 |
-
2017
- 2017-03-15 MA MA045324A patent/MA45324A/fr unknown
- 2017-03-15 JP JP2018546036A patent/JP2019508433A/ja active Pending
- 2017-03-15 WO PCT/US2017/022541 patent/WO2017161007A1/en not_active Ceased
- 2017-03-15 SG SG10201912908QA patent/SG10201912908QA/en unknown
- 2017-03-15 SG SG11201807526SA patent/SG11201807526SA/en unknown
- 2017-03-15 AU AU2017235545A patent/AU2017235545A1/en not_active Abandoned
- 2017-03-15 CA CA3016485A patent/CA3016485A1/en active Pending
- 2017-03-15 MX MX2018010847A patent/MX2018010847A/es unknown
- 2017-03-15 EP EP17767448.8A patent/EP3429626A4/en not_active Withdrawn
- 2017-03-15 KR KR1020187028273A patent/KR20180121571A/ko not_active Ceased
- 2017-03-15 KR KR1020237041743A patent/KR20230169462A/ko not_active Withdrawn
- 2017-03-15 US US16/085,511 patent/US11325980B2/en active Active
- 2017-03-15 KR KR1020227039721A patent/KR20220157515A/ko not_active Ceased
- 2017-03-15 BR BR112018068129-6A patent/BR112018068129A2/pt active Search and Examination
- 2017-03-15 CN CN201780013873.8A patent/CN108697801A/zh active Pending
- 2017-03-15 EA EA201891968A patent/EA201891968A1/ru unknown
-
2018
- 2018-09-02 IL IL261505A patent/IL261505A/en unknown
- 2018-09-07 MX MX2023008849A patent/MX2023008849A/es unknown
-
2022
- 2022-01-20 JP JP2022006944A patent/JP2022058676A/ja active Pending
- 2022-10-17 US US18/047,243 patent/US20230235083A1/en not_active Abandoned
-
2024
- 2024-03-14 JP JP2024039750A patent/JP2024075639A/ja active Pending
- 2024-03-21 AU AU2024201856A patent/AU2024201856A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508433A5 (https=) | ||
| Liao et al. | Model‐informed therapeutic dose optimization strategies for antibody–drug conjugates in oncology: what can we learn from US Food and Drug Administration–approved antibody–drug conjugates? | |
| Glassman et al. | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| Koga et al. | Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| US20230235083A1 (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| JP2018522850A5 (https=) | ||
| JP2019516748A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2016520082A5 (https=) | ||
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2019517505A5 (https=) | ||
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2021501776A5 (https=) | ||
| WO2011101328A3 (en) | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor | |
| JP2019524713A5 (https=) | ||
| CN102448497A (zh) | 在癌症治疗中的西仑吉肽的持续给药 | |
| KR20210084560A (ko) | Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제 | |
| Chakraborty et al. | A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma | |
| Pretelli et al. | Antibody-drug conjugates combinations in cancer treatment | |
| Hu et al. | Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: a focus on exposure-response analyses | |
| Richardson et al. | Antibody drug conjugates in the treatment of epithelial ovarian cancer | |
| Grimsley et al. | Monoclonal antibodies in cancer |